Start your appropriate patients with diabetes on Tresiba® (insulin degludec)

Prescribing Tresiba®

Injection
support

Cost and
coverage

Patient
support



Quick tips for prescribing Tresiba®
When sending prescribing information, be sure to specify the right formulation of Tresiba® for your patients:
- The U-100 pen has a maximum dose of 80 units per injection and is dosed in 1-unit increments
- The U-200 pen has a maximum dose of 160 units per injection and is dosed in 2-unit increments
- The U-100 vial holds a volume of 10 mL
Starting or converting adult patients
Find out how to start, convert, and titrate Tresiba® for your adult patients.

Supporting patients with their Tresiba® injection

Show your patients how to use Tresiba® FlexTouch®
Direct your patients to this easy-to-follow video that introduces them to the pen and illustrates how they can administer Tresiba®. Share the IFU video


Savings and coverage tools to help your patients start Tresiba®

Direct commercially insured patients to TresibaSavings.com to get a savings card ›
They will also automatically be enrolled in the Cornerstones4Care® support program.
Coverage for Tresiba® has grown and more of your patients may be covered than you think

NovoCare® provides information about financial assistance and patient access support
Novo Nordisk is committed to helping your patients throughout their treatment with support and access to insulin no matter what type of insurance they have, or even if they are without insurance. Through NovoCare®, we can help your patients find programs that may lower the cost of their Tresiba® or provide it free if they qualify.
Direct patients to NovoCare.com/letushelp to get help with costs.

Support for your patients
Tresiba® starter kit for patients
Help your patients get started from the comfort of their home at TresibaQuickResources.com. This page has information about how to inject, how to save, how to connect with support, and more.

Personalized diabetes management support built around your patients’ needs and goals

Leading a healthier life with diabetes can be tough, but Cornerstones4Care® is here to help. We've gathered expert advice and inspiration to help patients stay motivated and independent.
Patients have access to:

One-on-one sessions with a Diabetes Health Coach to answer questions, provide healthy eating ideas and tips. The Health Coach is ready to assist by phone, text, or email on a schedule that’s convenient for your patients

Bite-sized, everyday lessons on eating better, moving more, and treating diabetes that take under 5 minutes
Direct patients to Tresiba.com to get started
Request samplesb to start patients on Tresiba®
bYou must be a licensed practitioner who can legally prescribe medication in your state. (Request for product samples is limited to 1 request per health care professional.)

Indications and Usage for Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.
Important Safety Information
Contraindications
- Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients
Warnings and Precautions
- Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
- Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
- Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
- Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
- Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
- As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
- Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered
Adverse Reactions
- Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain
Drug Interactions
- There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
- Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
- Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
- Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
- Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine
Please click here for Tresiba® Prescribing Information.